Senti Biosciences, a business developing cancer treatments utilizing a brand-new programmable biology platform, stated it has actually raised $105 million in a brand-new round of financing led by the endeavor arm of life sciences giant Bayer. The company’s innovation utilizes new computational biological techniques to produce cell and gene therapies that can more exactly target specific […] The company is at first using its gene circuit technology platform to develop treatments that use what are called chimeric antigen receptor natural killer (CAR-NK) cells that can target cancer cells in the body and remove them. “The gene circuit gets you specificity … Right now when you utilize a CAR-T cell or a CAR-NK cell … you find a target and hope that it does not affect normal cells. “Over the previous 2 years, our team has actually created, built and tested thousands of sophisticated gene circuits to drive a robust product pipeline, focused at first on allogeneic CAR-NK cell treatments for difficult-to-treat liquid and strong growth indications,” Lu stated in a declaration. Developing gene circuits is a brand-new and expanding field with a number of gamers, consisting of Cell Design Labs, which was acquired by Gilead in 2017 for up to $567 million. …
With a multitude of collaborations with big pharmaceutical companies under its belt and the effective draw out of a minimum of one new business, Atomwise has actually already shown the worth of its maker learning platform for discovering and commercializing prospective small particle treatments for a host of conditions.
Now the company has actually raised$123 million in […]
Smaller sized, earlier-stage & business like StemoniX and SEngine Precision Medicine are likewise using Atomwise’s tech. And X-37 is just one of the companies that Atomwise has created to commercialize numerous brand-new molecules. Atomwise is far from the only business to believe that the application of machine learning innovations to drug discovery is a winning combination. It’s likewise why companies like DCVC, BV, Tencent, Y Combinator, Dolby Ventures, AME Cloud Ventures and 2, undisclosed insurance business have actually invested in the business’s latest round.”Business like Atomwise that are improving the cost curve are in the same vein of bringing therapies to market faster and less expensive….